Loading data for GALT — first visit, this takes a few seconds.
Galectin Therapeutics Inc. (GALT) Aktienkurs, Analyse & Daten
Innerer Wert
Analystenprognose
Aktienprognosen →Letzte Ergebnisse
| Gemeldet | Vs. Schätzung | YoY-Veränderung | |
|---|---|---|---|
| Umsatz | $0 | n/a | n/a |
| EPS | -$0,14 | -$0,05 | -16.67% |
Kennzahlen
- Geld
- 2.83
- Marktkapitalisierung
- 369M
- Umsatz (TTM)
- n/a
- Nettogewinn (TTM)
- -28M
- 0.39
- -0.43
- n/a
- -2.18
- KBV (TTM)
- -1.75
- KUV (TTM)
- n/a
- Termin Quartalszahlen
- n/a
- Brief
- 5.06
- Volumen
- 243,766
- Ø Vol. (20D)
- 663,690
- Eröffnung
- 3.92
- Vortagesschluss
- 3.90
- Tagesspanne
- 3.84 - 4.01
- 52-Wk Range
- 2.03 - 7.13
- Analyst
- n/a
- Kursziel
- n/a
- Dividenden
- n/a
- Ex-Dividenden-Datum
- n/a
Über Galectin Therapeutics Inc.
Profil ansehen →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Branche Biotechnology
Sektor Healthcare
IPO Datum Sep 4, 2002
Mitarbeiter 9
Börse NasdaqCM
Tickersymbol GALT
Website https://galectintherapeutics.com